We see what others don't

About Mundipharma

Opens Page

Our medicines

Opens Page

Careers

Opens Page

Partnering

Opens Page

Latest News

Mundipharma announces the positive outcome of the European Decentralised Procedure (DCP) for flutiform® k-haler®, a novel treatment for adolescents and adults with asthma

Oct 04 2017

Opens Page

For European trade and financial media only

CHMP positive opinion for opioid dependence treatment with Zubsolv®(buprenorphine and naloxone) in Europe

Sep 15 2017

Opens Page

For European medical media only

Mundipharma receives CHMP positive opinion for Nyxoid®(intranasal naloxone spray)

Sep 15 2017

Opens Page

For European medical media only


The Mundipharma global network of
independent associated companies:

Active in more than
120 worldwide markets;
30 in Europe
A presence across
six continents
.
Together, these businesses
employ more than
8,600 professionals
European sales exceeding
€1 billion and global sales
exceeding $3.4 billion

Supporting patients and communities

As we live longer, providing good quality medical care becomes an increasingly challenging task for the healthcare sector.

Network capabilities

Since our founding by physician entrepreneurs in 1952, the Mundipharma network of independent associated pharmaceutical companies has served the needs of patients and healthcare providers around the globe by providing novel medicines that address unmet medical needs.

Sharing clinical trial information and results

Clinical trial results for studies managed by Mundipharma Research and more information on our disclosure policy are available here.